Ofatumumab in AQP4-IgG Seropositive NMOSD

NCT05504694 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Neuromyelitis Optica Spectrum Disorder

Interventions

DRUG: Ofatumumab

Sponsor

Tang-Du Hospital

Collaborators

[object Object]